Summary.-The effects of methotrexate (MTX) and 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (BW50197) on the colony forming ability of L5178Y cells were compared. Two sub-lines of cells were used, one sensitive to methotrexate and the other resistant. In addition, the inhibitory effects of BW50197 against dihydrofolate reductase (DHFR) extracted from the MTX resistant-cells were compared with those of MTX and pyrimethamine. It was found that although BW50197 was a less effective inhibitor of DHFR than MTX, it was superior to MTX at high concentrations in killing MTX resistant cells, and this superiority increased with the time of exposure to the drugs. These findings suggest that (a) when antifolate compounds are screened for antitumour activity it is insufficient simply to assess them on the basis of their ability to inhibit DHFR and (b) BW50197 should be given clinically so as to achieve the highest possible tissue concentration for the longest possible time consistent with the safety of the patient.
concentrations in killing MTX resistant cells, and this superiority increased with the time of exposure to the drugs. These findings suggest that (a) when antifolate compounds are screened for antitumour activity it is insufficient simply to assess them on the basis of their ability to inhibit DHFR and (b) BW50197 should be given clinically so as to achieve the highest possible tissue concentration for the longest possible time consistent with the safety of the patient.
WHILE testing the effect of a series of diaminopyrimidines for antitumour activity against transplantable mouse tumours, Clarke et al. (1952) showed that one of this class of agents, 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (BW50197) was particularly effective in inhibiting the growth of the sarcoma 180. Further studies showed that this compound was also effective in controlling leukaemia (Burchenal et al., 1952) and the growth of the Ehrlich ascites tumour (Sugiura, 1953) in mice, and that it modified the growth of the chick embryo (Karnofsky, unpublished data) . Under the conditions of testing, BW50197 was the pyrimidine analogue most effective in inhibiting tumour growth. Subsequently Murphy et al. (1954) showed in a clinical study that BW50197 produced haematological improvement in 3 out of 12 children with acute leukaemia. Our interest in BW50197 was stimulated by the observation by Nichol (1968) that inhibition of a methotrexate resistant tumour (the Walker carcinoma 256) could be achieved by this drug which showed a more favourable therapeutic index against this tumour than pyrimethamine (Mishra, Rosen and Nichol, 1967; Sotobayashi, Rosen and Nichol, 1966) . Furthermore Geils et al. (1971) showed that pyrimethamine was effective in controlling some cases of meningeal leukaemia in man. Because diaminopyrimidines had been shown to possess antitumour activity and since BW50197 appeared superior in certain experimental systems, we felt that this compound merited further study. In this report we (Harrap et al., 1971) . These cells can still be killed provided that a sufficient extracellular concentration of the drug can be maintained for a long enough time (Harrap et al., 1971) . Clinically, however, a prolonged exposure to MTX is associated with severe toxicity to normal proliferating systems such as the bone marrow and gut (Bergsagel, personal communication 1970) , although very high concentrations can safely be given over short periods of time (Goldie, Price and Harrap, 1972; Djerassi et al., 1,972) . However, although BW50197 does produce haematological toxicity, it can be given over much longer periods than MTX (Murphy et al., 1954) . Therefore, since human tumours exist which are resistant to MTX by virtue of a transport defect (Kessel, Hall and Roberts, 1968) (Goldie, Furness and Price, 1973; Wood, Ferone and Hitchings, 1961) . Whatever the explanation, the important poinit is that cell viability assays are essential in the overall assessment of the biological activity of these agents. If agents are rejected purely on the basis of their inferior activity against DHFR, it is possible that potentially valuable antitumour agents will be missed. The second significant conclusion from these results is that far greater reduction in the cell viability of resistant cells is achieved when very high doses of BW50197 are given, and that this effectiveness increases with time. This suggests that, in contrast to previous practice, t,he maximum possible dose of BW50197 should be given for the longest possible time in MTX resistant tumours.
BWA50197 has a much longer half-life (180-200 hours) than MTX and is concentrated in certain tissues, so that tissue concentrations greater than plasma concentrations can be achieved. There are, however, certain practical obstacles to this course. For example, BW50197 reaches very high concentrations in the brain (Stickney et al., 1973) and so may produce convulsions. Also, a protracted and expensive course of folinic acid might be necessary to prevent bone marrow toxicity. In spite of this, it might be possible to administer BW50197 using the " kill and rescue " technique currently employed for MTX and suggested for pyrimethamine (Goldie et al., 1973) . In any event, these findings confirm the potential usefulness of diaminopyrimidines and we think it possible that BW50197, given carefully, might be effective in certain tumours resistant to MTX. We propose to carry out clinical studies along the lines indicated above.
